Discover how rheumatoid arthritis advances through distinct stages, the symptoms at each phase, and treatment approaches that ...

For the first time, researchers have found strong evidence that Epstein-Barr virus (EBV), which is best known for causing mononucleosis (or “mono”), may play a role in the development of Crohn’s ...

CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing -HAMPTON, N.J., ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

InflaRx (NASDAQ:IFRX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.27) ...

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP ...

US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic.

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.

Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with a weakened ...

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...